Compare KNSA & ADT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNSA | ADT |
|---|---|---|
| Founded | 2015 | 1874 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.8B |
| IPO Year | 2018 | 2017 |
| Metric | KNSA | ADT |
|---|---|---|
| Price | $63.61 | $6.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $60.86 | $7.75 |
| AVG Volume (30 Days) | 996.3K | ★ 8.3M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | ★ 225.00 | 29.63 |
| EPS | ★ 0.27 | N/A |
| Revenue | $677,564,000.00 | ★ $5,128,607,000.00 |
| Revenue This Year | $37.48 | $1.90 |
| Revenue Next Year | $17.87 | $2.91 |
| P/E Ratio | $232.74 | ★ N/A |
| Revenue Growth | ★ 60.09 | 4.70 |
| 52 Week Low | $26.27 | $6.24 |
| 52 Week High | $67.53 | $8.94 |
| Indicator | KNSA | ADT |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 55.84 |
| Support Level | $37.62 | $6.65 |
| Resistance Level | $67.53 | $7.09 |
| Average True Range (ATR) | 2.72 | 0.18 |
| MACD | -0.39 | 0.04 |
| Stochastic Oscillator | 46.82 | 58.61 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.